Shenzhen Foncoo Pharmaceutical Co., Ltd is a pharmaceutical enterprise incorporated on the base of former Shenzhen Kangrui Medicines Co., ltd, which specializes in R&D of new drugs and sales in the countrywide.
Foncoo Pharmaceutical Co., Ltd possesses a specialized team who are young, highly professional and diligent in learning with an average age of 29 years old, of which 86% have university degrees, 70% have university degrees in medicine, and the major management personnel have received systemic EMBA education. With a reasonable structure, a clear and perfect function, a fully–capital subsidiary called “Shenzhen Foncoo Pharmaceutical Technology Co., Ltd.” has been established in 2004.

Marketing network
       Foncoo Pharmaceutical has now successfully developed a whole set of marketing patterns with its unique characteristics, and has set up a powerful marketing network in the domestic prescription drug market. By dividing the whole domestic market into six big areas under which 29 offices at provincial level are set up and managed on the basis of areas and products sub-classification, our marketing team is proved to be high- efficient and stable. Besides, a powerful library of regional distributors containing over 2,000 units has been set up, and nearly 1,000 domestic distributors are cooperating with us at different levels at present. Our products have been sold to more than 2,000 hospitals in 30 provinces, municipalities, autonomous regions across the country, with an annual sales of prescription drugs more than RMB 400 million Yuan (calculated on the basis of the market prices). We have the high popularity and good reputation.

Combination of products
       Keeping developing new products is the core competitive power for the high-speed development of Foncoo Pharmaceutical. At present we are dealing with 8 products including two cephalosporin injections, one hemostasis-powder injection, one neurological powder injection, one powder injection for respiratory diseases and three oral Chinese patent medicines, among which five products have our own intellectual property and three products are sold by us as the national general agent or general dealer, such as Cefotiam Hydrochloride for Injection produced by General Pharmaceutical Factory of Harbin Pharmaceutical Group and Meclofenoxate Hydrochloride for Injection produced by Beijing Zizhu Pharmaceutical Co., Ltd. With an excellent performance in sales, we not only become the largest client of General Pharmaceutical Factory of Harbin Pharmaceutical Group, Beijing Zizhu Pharmaceutical Co., Ltd and Leshan Anjou Long march Pharmaceutical Co., Ltd on sales of new drugs but also are only general agency of General Pharmaceutical Factory of Harbin Pharmaceutical Group and Beijing Zizhu Pharmaceutical Co., Ltd at home. In addition, we will cooperate with the famous pharmaceutical enterprises such as Shandong Reyoung Pharmaceutical Co.,Ltd and Sichuan Dikang Sci&Tech Pharmaceutical Industry Co., Ltd to launch new products.
     With the development of the import drug,we establish the communication with more pharmaceuticals,including Korea,France,US,Japan,India and the countries of Latin America and established closely business relationship with them.

R&D strategy
      Develop high-quality medical products and improve the people’s health level is
Our mission. The strategy of the company in R&D is to finally possess the patent products with its own intellectual property. Shenzhen Foncoo Pharmaceutical Technology Co., Ltd is very strong in the capability of developing new drugs, with an annual investment of around RMB 10 million for it. At present, it is working on a joint project on researching and developing of a Category I Chinese traditional medicine injection and a Category I new drug for angiocardiopathy with a chemical compound patent. At present, application for several drug patents have already been delivered to the State Patent Bureau. Several new modified drugs shall be approved by the state and launched to the market in the coming years. In addition, the company has established a special department of affairs for imported drugs, which specializes in screening, investigation, negotiating and declaring of the imported drugs.

Informatization and brand construction
      With the safe and highly-efficient information data platform established earlier, the company was the first one which works through network and operates through OA system flow. Since its incorporation, the company has been building up its brand and image by carrying out the CIS project in an all around way with a vision of strategic development.

Enterprise expectation
    “The enterprise becomes an international enterprise with leading science and technology as well as outstanding service in the pharmaceutical industry” is our expectation. So we divided Five-year development strategic objective into three stages will be realized;
      Stage I: Associate with the famous enterprises at home and abroad to make the sale network became larger, more powerful and finer.
      Stage II: Became one of the powerful general agents of the specialized-subject high-rank imported drugs in China; to accomplish the project of new drugs of Category I with our own intellectual property, and to establish the production base so as to ensure the effective transformation of the scientific research results and the execution of brand strategy.
     Stage III: turn the company into a bigger hi-tech pharmaceutical enterprise of new style combining the scientific research, the industry and the trade into a whole

Operation conception: Through years of operation, we have set up a set of core values, which is innovate our products continously and service our customers wholeheartedly.

     Based on the co-operative ideas of “being faithful” and “win-win”, as did in the past, Shenzhen Foncoo Pharmaceutical Co., Ltd sincerely invites you to co-operate and jointly make development with us ！